ID   TRI63_HUMAN             Reviewed;         353 AA.
AC   Q969Q1; B4DN95; Q5T2I1; Q96BD3; Q96KD9; Q9BYV4;
DT   06-JUN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 153.
DE   RecName: Full=E3 ubiquitin-protein ligase TRIM63;
DE            EC=2.3.2.27;
DE   AltName: Full=Iris RING finger protein;
DE   AltName: Full=Muscle-specific RING finger protein 1;
DE            Short=MuRF-1;
DE            Short=MuRF1;
DE   AltName: Full=RING finger protein 28;
DE   AltName: Full=RING-type E3 ubiquitin transferase TRIM63 {ECO:0000305};
DE   AltName: Full=Striated muscle RING zinc finger protein;
DE   AltName: Full=Tripartite motif-containing protein 63;
GN   Name=TRIM63; Synonyms=IRF, MURF1, RNF28, SMRZ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLU-237, INTERACTION
RP   WITH TTN; TRIM54 AND TRIM55, SUBUNIT, TISSUE SPECIFICITY,
RP   DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.
RX   PubMed=11243782; DOI=10.1006/jmbi.2001.4448;
RA   Centner T., Yano J., Kimura E., McElhinny A.S., Pelin K., Witt C.C.,
RA   Bang M.-L., Trombitas K., Granzier H., Gregorio C.C., Sorimachi H.,
RA   Labeit S.;
RT   "Identification of muscle specific ring finger proteins as potential
RT   regulators of the titin kinase domain.";
RL   J. Mol. Biol. 306:717-726(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Iris;
RX   PubMed=12107412;
RA   Wistow G., Bernstein S.L., Ray S., Wyatt M.K., Behal A.,
RA   Touchman J.W., Bouffard G., Smith D., Peterson K.;
RT   "Expressed sequence tag analysis of adult human iris for the NEIBank
RT   project: steroid-response factors and similarities with retinal
RT   pigment epithelium.";
RL   Mol. Vis. 8:185-195(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Skeletal muscle;
RA   Stanchi F.;
RT   "Characterisation of MURF2, a new muscle-specific RING finger protein
RT   of the RBCC family that associates with microtubules.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, INTERACTION WITH SUMO2, MUTAGENESIS OF CYS-39;
RP   HIS-41; CYS-44 AND CYS-47, AND DOMAIN.
RX   PubMed=11283016; DOI=10.1074/jbc.M011208200;
RA   Dai K.-S., Liew C.-C.;
RT   "A novel human striated muscle RING zinc finger protein, SMRZ,
RT   interacts with SMT3b via its RING domain.";
RL   J. Biol. Chem. 276:23992-23999(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Heart, and Skeletal muscle;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   GLU-237.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=11679633; DOI=10.1126/science.1065874;
RA   Bodine S.C., Latres E., Baumhueter S., Lai V.K.-M., Nunez L.,
RA   Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K.,
RA   Pan Z.-Q., Valenzuela D.M., DeChiara T.M., Stitt T.N.,
RA   Yancopoulos G.D., Glass D.J.;
RT   "Identification of ubiquitin ligases required for skeletal muscle
RT   atrophy.";
RL   Science 294:1704-1708(2001).
RN   [9]
RP   SUBCELLULAR LOCATION, DOMAIN, FUNCTION, AND INTERACTION WITH GMEB1.
RX   PubMed=11927605; DOI=10.1083/jcb.200108089;
RA   McElhinny A.S., Kakinuma K., Sorimachi H., Labeit S., Gregorio C.C.;
RT   "Muscle-specific RING finger-1 interacts with titin to regulate
RT   sarcomeric M-line and thick filament structure and may have nuclear
RT   functions via its interaction with glucocorticoid modulatory element
RT   binding protein-1.";
RL   J. Cell Biol. 157:125-136(2002).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18468620; DOI=10.1016/j.jmb.2008.03.049;
RA   Hirner S., Krohne C., Schuster A., Hoffmann S., Witt S., Erber R.,
RA   Sticht C., Gasch A., Labeit S., Labeit D.;
RT   "MuRF1-dependent regulation of systemic carbohydrate metabolism as
RT   revealed from transgenic mouse studies.";
RL   J. Mol. Biol. 379:666-677(2008).
RN   [11]
RP   INTERACTION WITH CKM, AND FUNCTION.
RX   PubMed=18222470; DOI=10.1016/j.jmb.2007.11.049;
RA   Koyama S., Hata S., Witt C.C., Ono Y., Lerche S., Ojima K., Chiba T.,
RA   Doi N., Kitamura F., Tanaka K., Abe K., Witt S.H., Rybin V., Gasch A.,
RA   Franz T., Labeit S., Sorimachi H.;
RT   "Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy
RT   metabolism and protein synthesis.";
RL   J. Mol. Biol. 376:1224-1236(2008).
RN   [12]
RP   STRUCTURE BY NMR OF 119-169.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the B-box domain of the human tripartite motif-
RT   containing 63 protein.";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 117-161 IN COMPLEX WITH ZINC
RP   IONS, DOMAIN, AND SUBUNIT.
RX   PubMed=18795805; DOI=10.1021/bi800733z;
RA   Mrosek M., Meier S., Ucurum-Fotiadis Z., von Castelmur E., Hedbom E.,
RA   Lustig A., Grzesiek S., Labeit D., Labeit S., Mayans O.;
RT   "Structural analysis of B-Box 2 from MuRF1: identification of a novel
RT   self-association pattern in a RING-like fold.";
RL   Biochemistry 47:10722-10730(2008).
RN   [14]
RP   VARIANTS LEU-5; ARG-61; SER-73; CYS-86; HIS-86; PHE-101; ASP-126;
RP   MET-232; ASN-254; ILE-305; ASP-318; ASP-321 AND ARG-351.
RX   PubMed=24865491; DOI=10.3390/ijms15069302;
RA   Su M., Wang J., Kang L., Wang Y., Zou Y., Feng X., Wang D., Ahmad F.,
RA   Zhou X., Hui R., Song L.;
RT   "Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of
RT   hypertrophic cardiomyopathy.";
RL   Int. J. Mol. Sci. 15:9302-9313(2014).
CC   -!- FUNCTION: E3 ubiquitin ligase. Mediates the ubiquitination and
CC       subsequent proteasomal degradation of CKM, GMEB1 and HIBADH.
CC       Regulates the proteasomal degradation of muscle proteins under
CC       amino acid starvation, where muscle protein is catabolized to
CC       provide other organs with amino acids. Inhibits de novo skeletal
CC       muscle protein synthesis under amino acid starvation. Regulates
CC       proteasomal degradation of cardiac troponin I/TNNI3 and probably
CC       of other sarcomeric-associated proteins. May play a role in
CC       striated muscle atrophy and hypertrophy by regulating an anti-
CC       hypertrophic PKC-mediated signaling pathway. May regulate the
CC       organization of myofibrils through TTN in muscle cells.
CC       {ECO:0000269|PubMed:11927605, ECO:0000269|PubMed:18222470}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homodimer. Homooligomer and heterooligomer. Interacts
CC       with SUMO2, titin/TTN and GMEB1. Interacts with TRIM54 and
CC       probably with TRIM55 and TNNI3. Forms a ternary complex with RACK1
CC       and PRKCE (By similarity). Interacts with CKM. {ECO:0000250,
CC       ECO:0000269|PubMed:11243782, ECO:0000269|PubMed:11283016,
CC       ECO:0000269|PubMed:11927605, ECO:0000269|PubMed:18222470,
CC       ECO:0000269|PubMed:18795805}.
CC   -!- INTERACTION:
CC       Q8IX12:CCAR1; NbExp=2; IntAct=EBI-5661333, EBI-356265;
CC       P26641:EEF1G; NbExp=2; IntAct=EBI-5661333, EBI-351467;
CC       Q96RP9:GFM1; NbExp=2; IntAct=EBI-5661333, EBI-2255048;
CC       Q8IXM3:MRPL41; NbExp=2; IntAct=EBI-5661333, EBI-912501;
CC       Q9NP98:MYOZ1; NbExp=2; IntAct=EBI-5661333, EBI-744402;
CC       Q8WZ42:TTN; NbExp=3; IntAct=EBI-5661333, EBI-681210;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000250}. Cytoplasm,
CC       myofibril, sarcomere, M line. Cytoplasm, myofibril, sarcomere, Z
CC       line. Note=Colocalizes with TNNI3 in myocytes (By similarity).
CC       Localizes to the M- and Z-lines in skeletal muscle. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q969Q1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q969Q1-2; Sequence=VSP_055443;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Muscle specific. Selectively expressed in
CC       heart and skeletal muscle. Also expressed in the iris.
CC       {ECO:0000269|PubMed:11243782, ECO:0000269|PubMed:11283016,
CC       ECO:0000269|PubMed:11679633, ECO:0000269|PubMed:12107412}.
CC   -!- DEVELOPMENTAL STAGE: Expressed throughout all developmental
CC       stages. {ECO:0000269|PubMed:11243782}.
CC   -!- DOMAIN: The RING-type zinc finger mediates interaction with SUMO2
CC       and localization to the nucleus. Also required for the E3
CC       ubiquitin ligase activity (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The B box-type zinc finger mediates homodimerization.
CC       {ECO:0000269|PubMed:11283016, ECO:0000269|PubMed:11927605,
CC       ECO:0000269|PubMed:18795805}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-14 is the initiator.
CC       {ECO:0000305}.
CC   -!- CAUTION: Variant Arg-351 is erroneously reported as Trp-351 in
CC       PubMed:24865491. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK52497.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC       Sequence=AAK52497.1; Type=Miscellaneous discrepancy; Note=Sequencing errors.; Evidence={ECO:0000305};
CC       Sequence=CAC33173.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ291713; CAC33173.1; ALT_INIT; mRNA.
DR   EMBL; AF353673; AAK39519.1; -; mRNA.
DR   EMBL; AJ276484; CAC81706.1; -; mRNA.
DR   EMBL; AF361946; AAK52497.1; ALT_SEQ; mRNA.
DR   EMBL; AK056942; BAB71318.1; -; mRNA.
DR   EMBL; AK297820; BAG60157.1; -; mRNA.
DR   EMBL; AL391650; CAI17133.1; -; Genomic_DNA.
DR   EMBL; BC080529; AAH80529.1; -; mRNA.
DR   CCDS; CCDS273.1; -. [Q969Q1-1]
DR   RefSeq; NP_115977.2; NM_032588.3. [Q969Q1-1]
DR   UniGene; Hs.279709; -.
DR   PDB; 2D8U; NMR; -; A=119-169.
DR   PDB; 3DDT; X-ray; 1.90 A; A/B/C=117-161.
DR   PDB; 4M3L; X-ray; 2.10 A; A/B/C/D=214-271.
DR   PDBsum; 2D8U; -.
DR   PDBsum; 3DDT; -.
DR   PDBsum; 4M3L; -.
DR   ProteinModelPortal; Q969Q1; -.
DR   SMR; Q969Q1; -.
DR   BioGrid; 124195; 92.
DR   IntAct; Q969Q1; 37.
DR   MINT; MINT-6492114; -.
DR   STRING; 9606.ENSP00000363390; -.
DR   iPTMnet; Q969Q1; -.
DR   PhosphoSitePlus; Q969Q1; -.
DR   BioMuta; TRIM63; -.
DR   DMDM; 21362898; -.
DR   MaxQB; Q969Q1; -.
DR   PaxDb; Q969Q1; -.
DR   PeptideAtlas; Q969Q1; -.
DR   PRIDE; Q969Q1; -.
DR   DNASU; 84676; -.
DR   Ensembl; ENST00000374272; ENSP00000363390; ENSG00000158022. [Q969Q1-1]
DR   GeneID; 84676; -.
DR   KEGG; hsa:84676; -.
DR   UCSC; uc001bli.3; human. [Q969Q1-1]
DR   CTD; 84676; -.
DR   DisGeNET; 84676; -.
DR   GeneCards; TRIM63; -.
DR   HGNC; HGNC:16007; TRIM63.
DR   MIM; 606131; gene.
DR   neXtProt; NX_Q969Q1; -.
DR   OpenTargets; ENSG00000158022; -.
DR   PharmGKB; PA34431; -.
DR   eggNOG; ENOG410ITEN; Eukaryota.
DR   eggNOG; ENOG4110918; LUCA.
DR   GeneTree; ENSGT00760000118878; -.
DR   HOGENOM; HOG000231156; -.
DR   HOVERGEN; HBG071242; -.
DR   InParanoid; Q969Q1; -.
DR   KO; K10655; -.
DR   OMA; DGNPMEN; -.
DR   OrthoDB; EOG091G071N; -.
DR   PhylomeDB; Q969Q1; -.
DR   TreeFam; TF331669; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; Q969Q1; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; TRIM63; human.
DR   EvolutionaryTrace; Q969Q1; -.
DR   GeneWiki; TRIM63; -.
DR   GenomeRNAi; 84676; -.
DR   PRO; PR:Q969Q1; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000158022; -.
DR   CleanEx; HS_TRIM63; -.
DR   Genevisible; Q969Q1; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031430; C:M band; IEA:UniProtKB-SubCell.
DR   GO; GO:0005874; C:microtubule; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0030018; C:Z disc; IEA:UniProtKB-SubCell.
DR   GO; GO:0004871; F:signal transducer activity; NAS:UniProtKB.
DR   GO; GO:0031432; F:titin binding; IDA:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006936; P:muscle contraction; IEA:Ensembl.
DR   GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; IEA:Ensembl.
DR   GO; GO:0014878; P:response to electrical stimulus involved in regulation of muscle adaptation; ISS:UniProtKB.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0014732; P:skeletal muscle atrophy; IEA:Ensembl.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR017903; COS_domain.
DR   InterPro; IPR027370; Znf-RING_LisH.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00643; zf-B_box; 1.
DR   Pfam; PF13445; zf-RING_UBOX; 1.
DR   SMART; SM00336; BBOX; 1.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS51262; COS; 1.
DR   PROSITE; PS50119; ZF_BBOX; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Coiled coil; Complete proteome;
KW   Cytoplasm; Metal-binding; Muscle protein; Nucleus; Polymorphism;
KW   Reference proteome; Transferase; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    353       E3 ubiquitin-protein ligase TRIM63.
FT                                /FTId=PRO_0000056290.
FT   DOMAIN      267    325       COS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00586}.
FT   ZN_FING      23     79       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     117    159       B box-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00024}.
FT   REGION       74    218       Interaction with TTN.
FT                                {ECO:0000269|PubMed:11243782}.
FT   COILED      207    269       {ECO:0000255}.
FT   VAR_SEQ     104    131       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055443.
FT   VARIANT       5      5       S -> L (rare variant; found in a patient
FT                                with hypertrophic cardiomyopathy; unknown
FT                                pathological significance;
FT                                dbSNP:rs762015648).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074092.
FT   VARIANT      61     61       S -> R. {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074093.
FT   VARIANT      73     73       F -> S (rare variant; found in a patient
FT                                with hypertrophic cardiomyopathy; unknown
FT                                pathological significance;
FT                                dbSNP:rs758754060).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074094.
FT   VARIANT      86     86       R -> C (rare variant; found in a patient
FT                                with hypertrophic cardiomyopathy; unknown
FT                                pathological significance;
FT                                dbSNP:rs529429430).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074095.
FT   VARIANT      86     86       R -> H (rare variant; found in a patient
FT                                with hypertrophic cardiomyopathy; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074096.
FT   VARIANT     101    101       I -> F (rare variant; found in a patient
FT                                with hypertrophic cardiomyopathy; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074097.
FT   VARIANT     126    126       E -> D (in dbSNP:rs142601731).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074098.
FT   VARIANT     232    232       T -> M (rare variant; found in a patient
FT                                with hypertrophic cardiomyopathy; unknown
FT                                pathological significance;
FT                                dbSNP:rs376414719).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074099.
FT   VARIANT     237    237       K -> E (in dbSNP:rs2275950).
FT                                {ECO:0000269|PubMed:11243782,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_020116.
FT   VARIANT     254    254       D -> N. {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074100.
FT   VARIANT     305    305       M -> I. {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074101.
FT   VARIANT     318    318       A -> D (rare variant; found in a patient
FT                                with hypertrophic cardiomyopathy; unknown
FT                                pathological significance;
FT                                dbSNP:rs201397530).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074102.
FT   VARIANT     321    321       A -> D. {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074103.
FT   VARIANT     351    351       G -> R (in dbSNP:rs202001619).
FT                                {ECO:0000269|PubMed:24865491}.
FT                                /FTId=VAR_074104.
FT   MUTAGEN      39     39       C->A: Loss of SUMO2-binding.
FT                                {ECO:0000269|PubMed:11283016}.
FT   MUTAGEN      41     41       H->A: Loss of SUMO2-binding.
FT                                {ECO:0000269|PubMed:11283016}.
FT   MUTAGEN      44     44       C->A: Loss of SUMO2-binding.
FT                                {ECO:0000269|PubMed:11283016}.
FT   MUTAGEN      47     47       C->A: Loss of SUMO2-binding.
FT                                {ECO:0000269|PubMed:11283016}.
FT   STRAND      123    125       {ECO:0000244|PDB:3DDT}.
FT   STRAND      132    134       {ECO:0000244|PDB:3DDT}.
FT   TURN        135    138       {ECO:0000244|PDB:3DDT}.
FT   STRAND      139    141       {ECO:0000244|PDB:3DDT}.
FT   HELIX       143    148       {ECO:0000244|PDB:3DDT}.
FT   TURN        150    153       {ECO:0000244|PDB:3DDT}.
FT   STRAND      156    158       {ECO:0000244|PDB:3DDT}.
FT   TURN        159    161       {ECO:0000244|PDB:2D8U}.
FT   HELIX       214    267       {ECO:0000244|PDB:4M3L}.
SQ   SEQUENCE   353 AA;  40248 MW;  9BE4B1505039BC86 CRC64;
     MDYKSSLIQD GNPMENLEKQ LICPICLEMF TKPVVILPCQ HNLCRKCAND IFQAANPYWT
     SRGSSVSMSG GRFRCPTCRH EVIMDRHGVY GLQRNLLVEN IIDIYKQECS SRPLQKGSHP
     MCKEHEDEKI NIYCLTCEVP TCSMCKVFGI HKACEVAPLQ SVFQGQKTEL NNCISMLVAG
     NDRVQTIITQ LEDSRRVTKE NSHQVKEELS QKFDTLYAIL DEKKSELLQR ITQEQEKKLS
     FIEALIQQYQ EQLDKSTKLV ETAIQSLDEP GGATFLLTAK QLIKSIVEAS KGCQLGKTEQ
     GFENMDFFTL DLEHIADALR AIDFGTDEEE EEFIEEEDQE EEESTEGKEE GHQ
//
